Redmile Group »

Immunome shares owned by Redmile Group

Quarter-by-quarter ownership of Immunome (IMNM) shares owned by Redmile Group from 13F filings

Historical chart of Redmile Group investment in Immunome

Tip: Access up to 7 years of quarterly data

All positions including Immunome held by Redmile Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immunome by Redmile Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $42M 3.9M 10.70

More positions owned by Redmile Group

ImmunoGen
Krystal Biotech (KRYS)
Amicus Therapeutics (FOLD)
Scholar Rock Hldg Corp (SRRK)
Rayzebio
Augmedix (AUGX)
Deciphera Pharmaceuticals (DCPH)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Regenxbio Inc equity us cm (RGNX)
Biohaven (BHVN)
Zymeworks Del (ZYME)
Livanova SHS (LIVN)
Alx Oncology Hldgs (ALXO)
Catalent (CTLT)
Fate Therapeutics (FATE)

View all positions for Redmile Group

Top funds holding Immunome

EcoR1 Capital
Redmile Group
Vanguard Group
Henderson Group
Avidity Partners Management
T. Rowe Price Associates
Point72 Asset Management
Brown Advisory Holdings Incorporated
Alpine Partners VI
TD Asset Management
Prentice Capital Management
Jane Street
Laurion Capital Management
Barclays
HPM Partners

View all funds holding Immunome